All In Biotech

Drug Trial Radar · NCT07503561

A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection

A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Operationally Seamless Phase 2/3 Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of AIC263029 in the Treatment of BKV Infection in Kidney Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 5, 2026

Primary completion

Sep 17, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if AIC263029 is safe and well tolerated in adult kidney transplant recipients with BK virus (BKV) in the blood (viremia). The study will also examine how the body processes AIC263029 and whether it lowers BKV levels in the blood. Researchers will compare AIC263029 to a placebo (a look-alike injection with no active drug). Participants will be assigned by chance to receive AIC263029 or placebo and will receive weekly injections under the skin for 4 weeks. Participants will have clinic visits and blood tests during treatment and follow-up to monitor safety and measure BKV levels, and will be followed for up to about 24 weeks after treatment.

Conditions

  • BK Virus Infection
  • BKV Infection
  • Kidney Transplant

Interventions

  • AIC263029Drug

    AIC263029 supplied in vials for injection (110 mg/mL) and administered by subcutaneous injection; Part A uses weekly dosing over 4 weeks in planned dose cohorts (100 mg, 200 mg, 330 mg).

  • PlaceboDrug

    Matching placebo administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of treatment-emergent adverse events (TEAEs)Time frame: Day 1 to Day 30 of the dosing period.

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Hospital

    Birmingham, Alabama · Recruiting

  • Keck Hospital of University of Southern California (USC)

    Los Angeles, California · Recruiting

  • UCLA College of Medicine

    Los Angeles, California · Recruiting

  • Tampa General Hospital

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • University of Maryland Medical Center

    Baltimore, Maryland · Recruiting

  • Barnes-Jewish Hospital - St. Louis (Washington University Medical Campus)

    St Louis, Missouri · Recruiting

  • Cooperman Barnabas Medical Center

    Livingston, New Jersey · Recruiting

  • New York-Presbyterian - Weill Cornell Medical Center

    New York, New York · Recruiting

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, Pennsylvania · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.